Recently published Infectious Diseases Society of America (IDSA) antimicrobial stewardship guidelines recommend that cost savings be measured "as a way to justify continued administrative support for antimicrobial stewardship program (ASP) activities" [1] . Though stewardship programs are primarily in place for patient safety, in reality programs are often asked to justify the investment in cost savings. Antimicrobial stewardship cost models are complex, and various approaches are used [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] . Lack of methodological detail in published manuscripts regarding cost models often renders results difficult to understand and impossible to compare. The IDSA guidelines recommend that anti-infective costs "be measured based on prescriptions or administrations instead of purchasing data, and normalized to account for patient census" [1] . Though limitations to this approach still exist, this new standard represents an opportunity to make cost assessments more uniform and comparable among centers.
This publication seeks to implement this recommendation using a successful stewardship program as the model. Children's Hospital Colorado (CHCO) significantly reduced anti-infective use since implementation of handshake stewardship in 2013 [14] . Overall anti-infective (antibacterial, antifungal, antiviral) days of therapy (DOT) per 1000 patient-days (PD) were reduced by 11%, or 103 DOT/1000 PD, placing CHCO among the lowest users in the national pediatric database (Pediatric Hospital Information Systems [PHIS]) [15] . The associated cost analysis endorsed only a minimal impact, though it was based on pharmacy purchasing data, a clear limitation. Using the same time periods, we sought to reanalyze the cost savings per the 2016 IDSA guidelines, using patient-level anti-infective administration data from the electronic medical record (EMR), and compared that to both the CHCO pharmacy purchasing data, and patient-level billed administration data in a national database, PHIS [15, 16] .
periods. Outcomes evaluated were total anti-infective costs and costs per 1000 PD, and then a subanalysis by class (antibacterial, antifungal, antiviral). This study was conducted at CHCO, a freestanding tertiary care academic pediatric hospital with 444 licensed beds. The review was approved by the Organizational Research Risk and Quality Improvement Review Panel at CHCO. The comparison periods included pre-ASP (October 2010-September 2011), planning (October 2011-September 2013), and post-ASP (October 2013-September 2014) periods, the same periods as a previous publication describing the method and impact of our Handshake Stewardship program. The periods purposefully encompass the same months of the year to minimize the influence of seasonal variation. Regarding stewardship activities, the pre-ASP phase included only an antibiogram and an intravenous-to-oral switch policy; the planning phase included groundwork for provider acceptance, report and EMR tool development, and clinical care guideline development; the post-ASP phase included an approach deemed "Handshake Stewardship. " This strategy does not include preauthorization, but rather involves prospective audit and feedback of all anti-infectives (antibacterials, antifungals, antivirals) at the 24-hour and 72-hour time-points by both an ASP physician and pharmacist. Interventions identified by the stewards are communicated in person to providers on over 16 teams during clinical rounds. More detailed descriptions of this strategy are published elsewhere [14] .
Acquisition of Cost Data and Explanation of Data Elements
Cost data were acquired using 3 different methods: pharmacy purchasing data, patient-level anti-infective administration data from the EMR, and patient-level billed administration data in a national database, PHIS; these datasets will hereafter be called "EMR data" and "PHIS data, " respectively. For contextual comparison and an understanding of how these data are generated, Figure 1 and Table 1 compare the methods in various categories.
Pharmacy expenditures were partially reported in our previous publication, though this was antibacterials only [14] . CHCO purchasing data were acquired from available pharmacy records and datasets; these data are not kept electronically. At CHCO, these data are purged after 3 years so no costs were available for the pre-ASP period. Data only included drug purchased from usual buyers and vendors, and thus may not include nonformulary drugs or drugs purchased via other methods during shortages. The patient admissions and PD were obtained from hospital census data based on bed occupancy at midnight. This number was used to calculate the pharmacy purchasing cost per 1000 PD.
CHCO uses Epic software. For each medication administered to a patient, an associated drug charge and drug cost are attributed. To arrive at cost, the patient-level amount (g/mg or units) of administered drug is multiplied by that specific medication's average wholesale price (AWP). The AWP is a United States national pricing benchmark; it is updated in Epic every 1-3 months. The report is available in Epic as the "charge summary report" and can be used to determine the underlying costs of the medication-specific charges. Anti-infective costs were extracted using a built report (by authors M. M. and A. L. H.) and compiled for the study time periods. Anti-infectives were grouped into class (antibacterial, antifungal, antibacterial) by A. L. H. The patient admissions and PD were obtained from hospital census data based on bed occupancy at midnight. This number was used to calculate the EMR data in cost per 1000 PD, as recommended in the IDSA guideline. DOT was calculated as previously reported [14] .
Data in PHIS are submitted by >42 freestanding pediatric hospitals in the United States. Our specific hospital sends the patient-specific drug charges (based on administered, billed drug) to PHIS quarterly. The PHIS charges and DOT were extracted using a specially built query (by author C. T.), and charges converted to approximate costs using a ratio of cost to charge (RCC) (submitted yearly by each hospital to Centers for Medicaid and Medicare Services [CMS] and to the PHIS database). For this analysis, the pharmacy-specific RCC (namely, the PHIS RCC codes 6 and 7) was used, rather than the overall hospitalization RCC. Anti-infectives were identified using the Clinical Transaction Codes for anti-infectives, grouped into class (antibacterial, antifungal, antibacterial) by A. L. H. Patient discharges and PD were also extracted from PHIS, and used to calculate the PHIS data in cost per 1000 PD. PHIS charges per patient receiving were also assessed for each class of anti-infective (antibacterial, antifungal, antiviral) for the time periods.
Cost Estimate Calculations
Cost estimates were then calculated for the various time periods using formulas built into an Excel spreadsheet. Using the drug costs by each method and the PD, a total anti-infective cost for time period and cost of anti-infectives per 1000 PD was calculated and compared between methods, and over time. Differences in time periods were calculated based on the calculated cost for the latter time period as compared to what the cost would have been if the cost per 1000 PD from the comparison time period was static. Data were then broken down into therapeutic class.
RESULTS
Overall costs comparing pharmacy purchasing, EMR, and PHIS data acquisition methods are shown in Table 2 . Expressed as the cost per 1000 PD as suggested by the IDSA guidelines, pharmacy purchasing cost is $10 545 per 1000 PD during the planning phase, compared to $10 451 per 1000 PD in the post phase. For those same periods, the EMR data endorse a cost of $56 320 (planning) per 1000 PD to $43 535 per 1000 PD (post), as compared to the PHIS data with a cost of $70 870 per 1000 PD (planning) to $49 489 per 1000 PD (post). This results in overall cost savings for all methods. For the pharmacy purchasing data, there is a total savings of $54 656 per year when comparing the post-ASP to the planning period. This is compared to the EMR data, which endorse a savings of $1 184 336 for the same period, and PHIS data, which endorse a savings of $2 117 522. When the post period is instead compared to the pre period (for which we have no pharmacy purchasing data), EMR data endorse a total savings of $1 023 439, and PHIS a savings of $1 635 228. Details are shown in Table 2 .
Drug class cost differences comparing EMR and PHIS data are shown in Supplementary Table 2. In terms of total expenditures by anti-infective class (antibacterial, antifungal, antiviral), antibacterials incur the most expense, followed by antifungals, then antivirals. On further analysis of CHCO EMR data, antiviral costs are heavily influenced by use of inhaled ribavirin, which costs $29 953 per 6-g vial (AWP 2016 pricing). The largest overall cost savings pre to post were realized in antibacterials and antifungals (Supplementary Table 2 ). Though antibacterials incur the most overall cost, they are also given to more patients, so we also assessed the anti-infective cost per patient receiving that class (rather than all patients) in PHIS. The cost per patient receiving is highest for antifungals, stable at $1370 per patient in the pre and post periods. Comparatively, the per-patient receiving costs of antivirals were $355 pre vs $421 post and antibacterials were $424 pre vs $372 post.
DISCUSSION
Dramatic differences in estimated cost savings associated with a pediatric ASP were observed when comparing pharmacy purchasing data, patient-level anti-infective administration data from the EMR, and patient-level billed administration data in a national database, PHIS (Table 2) . Pharmacy purchasing data appeared to markedly underestimate cost savings as compared with EMR and PHIS data, reflecting the known limitations of Hypothetical example for 1 month using 400 DOT/1000 PD of ceftriaxone (AWP price $1.75/g) In month of December, pharmacy purchases 6-mo supply of ceftriaxone for $8400
In the month of December, exact grams of ceftriaxone administered are extracted from EMR, equaling 720 g. This 720 g × AWP cost = $1260.
In the month of December, patients are billed for 720 g of ceftriaxone. This charge is extracted from PHIS. This charge is multiplied times the PHIS RCC, cost is = $1575.
Abbreviations: AWP, average wholesale price for the United States (updated monthly); DOT, days of therapy; EMR, electronic medical record; PD, patient-days; PHIS, Pediatric Hospital Information Systems; RCC, ratio of cost to charge.
this method. PHIS data resulted in a larger estimated cost savings compared with EMR data, reflecting PHIS' inclusion of pharmacy operating costs. Although the more valid of these 2 models (EMR and PHIS) may be argued, the estimated cost savings from the 2 models both appear more accurate than CHCO pharmacy purchasing data, and are comparable in scale and percentage savings. This analysis supports more than sufficient savings in drug acquisition costs to offset the fixed costs of our ASP. Stewardship efforts focus on patient safety, and a decrease in cost is viewed as an "added benefit. " However, most ASPs generally require cost justification to gain or maintain support for a program, which at our hospital includes an MD (full-time equivalent [FTE] 0.5), a PharmD (FTE 1.0), and a data analyst (FTE 0.2), for a total of approximately $250 000 per year (internal data). Support for ASP programs is viewed favorably by the Joint Commission, CMS, and US News and World Report, yet hospitals are still interested in the concrete cost reductions represented by a lower hospital anti-infective acquisition budget. Cost savings reported in the literature are not easily applied to other institutions due to lack of description and standardization of the methodology, leaving new programs creating business plans at a loss in attempting to calculate projected cost savings.
Patient-level antibiotic administration and census data from the EMR are widely accessible in both pediatric and adult hospitals, and thus allows consistency and comparability, justifying the IDSA recommendation to use this approach. EMR data are derived from the patient's exact dose multiplied by the AWP price. The AWP price is likely to be higher than what most hospitals actually pay (due to competitive bidding and collective buying), though some see this as a "built in" way to assess pharmacy overhead. Alternatives to the AWP include actual pharmacy drug costs multiplied by the amount of drug used from the EMR [34] , but this is not built into EMR systems and these data are not formulation specific (eg, frozen bags vs powder vials, this influences cost), and thus using actual costs is cumbersome. In addition, the data are usually considered proprietary, so published literature will always lack detail, making comparisons difficult. Likely due to the proprietary nature of these data, we could not find publications comparing AWP with pharmacy pricing, but anecdotally the percentage of the AWP paid is widely variable and depends upon the drug. This methodology is most applicable in the United States as the AWP is US pricing, but if comparability to US hospitals is desired or if an institution knows what percentage of the AWP they usually pay, AWP is applicable. Alternatively, if there is an in-country AWP equivalent, it is easily substituted for the AWP to obtain more country-relevant numbers. Overall, EMR data using the AWP are reproducible, comparable and consistent, making this the most attractive method for both adult and pediatric hospitals. For example, our EMR data endorse a purchase savings of 21% per 1000 PD pre to post-ASP; though the savings may not truly total $1 023 349, the savings are likely around 21% of the actual anti-infective budget. The "excess" may also be considered a way to incorporate operational costs [17] .
PHIS data are based upon charges, and then cost is calculated using an RCC submitted by each hospital yearly. The methods hospitals use to calculate RCCs are highly variable, and include various degrees of hospital operational costs. Our PHIS data endorse larger savings than our EMR data, but savings are a comparable 23% per 1000 PD pre to post-ASP. Notably, in PHIS the ratio used for conversion must be chosen carefully. We used the pharmacy-specific RCC, whereas the overall hospitalization RCC resulted in over double the estimated cost savings (data not shown). PHIS is only comparable within the same dataset (PHIS), whereas EMR data based on wholesale pricing is comparable across centers. Centers should decide on a model for cost assessment and be consistent across time, understanding the misgivings to each dataset ( Figure 1 and Table 1 ).
The deficiencies of purchasing data are limitations to our study, though also inherently one of the points of our study. However, these data at CHCO may be more flawed than other centers, and other centers may save records for longer periods, so the differences between datasets we observed may not be so marked at other institutions. In fact, other centers report significant cost savings using pharmacy purchasing data [2, 7, [18] [19] [20] . Notably, these data are still difficult to compare as they are obtained and reported with a variety of methods, and a reported cost reduction may be attributable to bulk buying practices, better contract pricing, or incomplete purchasing reports rather than savings attributable to an ASP. For example, if there is little change in use of a class but savings are reported, this might be attributable to bulk buying or changes in contract pricing [18] . Our purchasing data are clearly flawed, but it is likely that many centers suffer from similar problems, as much of the issue comes from how drug purchases are reported to hospitals by suppliers, the many avenues of purchases and varied databases, and how hospitals then categorize purchases, which is often not uniform or accounting-friendly. We suspect the lack of cost data in many ASP manuscripts reflects the reality of these challenges. Unfortunately, many manuscripts that do report cost do not provide sufficient methodology to understand exactly what is being reported.
In addition, our data are not adjusted for inflation, though this would only make the savings greater; this can be done using data for inflation in general, or healthcare inflation in particular [4] . The last limitation is that our data are not compared to projected costs-that is, if we had continued with our rise in anti-infective use as demonstrated by the trajectory in our pre-ASP period [14] -but this again would only increase savings.
To add context and perspective to cost savings, it is helpful to also report the changes in the DOT/1000 PD, changes in cost per patient receiving that drug class, and changes in the percentage of patients receiving that class [14] . One can thus gain a sense of whether costs decrease because of decreased DOT, decreased durations, or decreased number of patients receiving, or conversely, if use has not changed and the decrease is due to changes in drug acquisition pricing alone. This can help inform intervention strategies.
Notably, drug costs are only one component of the cost benefit to stewardship in a bundled (rather than fee-for-service) reimbursement model [12, 13, 21] . Reductions in pediatric Clostridium difficile saves $93 000 per case [22] , aversion of hospital-acquired and anti-infective resistant infection saves $1000-$100 000 per case [3, [23] [24] [25] [26] [27] [28] [29] , decreased use of drug monitoring saves approximately $50/drug level (internal data), and adverse drug reactions cost $3000-$8000 each [30] . There is also a safety component to appropriate choice and dose of drug, with associated improved outcomes, higher cure rates, and shorter lengths of stay [2, 19, 20, 31] . Taking these savings into account is very complex, but reported in the literature [5, 6, [19] [20] [21] [31] [32] [33] .
Estimates of cost savings for ASPs vary dramatically based on methodology used; therefore, the various methods must be applied and interpreted with caution. There are apparent strengths to the proposed IDSA guideline metric recommending measuring anti-infective costs based on administrations standardized by census. EMR data most readily lend themselves to this in that they are feasibly measurable by hospitals, relatively standardized in methodology, and comparable across centers if reported in uniform units such as cost/1000 PD. Because the EMR data method is based on the AWP, it likely overestimates actual drug acquisition costs, but this limitation is outweighed by its benefits, and arguably may be viewed as incorporating pharmacy overhead. The EMR metric applied here is generalizable to both pediatric and adult hospitals, though the total impact on cost will depend on overall reductions in use and which agents in particular are reduced; we achieved a 20% reduction in cost with a 10% decrease in overall antimicrobial use.
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